Skip to main
EVAX

EVAX Stock Forecast & Price Target

EVAX Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Evaxion is a clinical-stage TechBio company that has developed a proprietary AI platform, AI-Immunology, which has shown promise in developing novel vaccines for both oncology and infectious diseases. The company's pivot into autoimmune disease indications is a strategic move that could potentially expand their market and revenue potential. Additionally, their development of off-the-shelf therapies, such as EVX-04, may address scalability and time-to-treatment concerns and attract investors.

Bears say

Evaxion is a clinical-stage TechBio company that has a promising AI platform and a pipeline of novel personalized vaccines for cancer and infectious diseases. However, the group's financials may be suffering as their lead personalized neoantigen vaccine, EVX-01, had a low overall response rate of 75% and a relatively small sample size of patients (16) in their two-year efficacy results. Investors should closely monitor the company's next major clinical update, which includes three-year efficacy data.

EVAX has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evaxion Biotech A/S and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evaxion Biotech A/S (EVAX) Forecast

Analysts have given EVAX a Strong Buy based on their latest research and market trends.

According to 4 analysts, EVAX has a Strong Buy consensus rating as of Jun 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evaxion Biotech A/S (EVAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.